Effectiveness of Qualia Magnesium+® Supplementation on RBC Magnesium Levels

This is a randomized, double-blind, placebo-controlled parallel trial designed to evaluate the effectiveness of Qualia Magnesium+® supplementation on red blood cell (RBC) magnesium levels in adults aged 21 and older. Approximately 100 participants with baseline RBC magnesium levels below 6.0 mg/dL will be randomly assigned to receive either Qualia Magnesium+ or a placebo. Participants will take 2 capsules daily in the evening, with or without food, for a duration of 12 weeks. The primary outcome is the between-group change in RBC magnesium levels from baseline to Week 12. Secondary outcomes include assessments of sleep quality, perceived stress, magnesium status, and safety and tolerability. Data collection will occur through lab bloodwork and electronic questionnaires.

NCT Number	NCT06979648
Lead Sponsor	Qualia Life Sciences
Conditions	Magnesium Deficiency
Enrollment	100 participants
Start Date	2025-05-21
Primary Completion	2025-08-21 (estimated)
Study Completion	2025-09-21 (estimated)
Updated on ClinicalTrials.gov	2025-05-20